ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2026
Evaluating a new partner management strategy for bacterial sexually transmitted infections after a change in 2020 in Amsterdam, the Netherlands, 2017 to 2023.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUNDFrom 1 March 2020, the Centre for Sexual Health Amsterdam limits presumptive treatment for chlamydia or gonorrhoea to clients notified by steady partners. Treatment after notification by non-steady partners requires a positive test result.AIMWe aimed to evaluate this change in policy on unnecessary antibiotic treatment, time to treatment and lost to follow-up clients.METHODSWe included consultations (with testing) following partner notification for chlamydia or gonorrhoea between 1 March 2017 and 1 March 2023. Primary outcome was unnecessary antibiotic treatment (presumptive treatment with negative test result) before vs after the policy change. We also assessed return for treatment of confirmed and not presumptively treated individuals after the policy change.RESULTSFrom 4,579 consultations, unnecessary antibiotics were prescribed for 786/1,318 (59.6%) clients for chlamydia and 729/1,117 (65.3%) clients for gonorrhoea before 1 March 2020. After 1 March 2020, this decreased to 324/1,275 (25%) and 341/1,369 (25%), respectively, corresponding to a relative reduction of 58% for chlamydia (adjusted relative risk (aRR): 0.42; 95% confidence interval (CI): 0.37-0.47) and 63% (aRR: 0.37; 95% CI: 0.33-0.42) for gonorrhoea. After the policy change, clients not given presumptive treatment but later diagnosed returned after a median of 7 days (interquartile range (IQR): 5-8) for chlamydia and 6 days (IQR: 4-7) for gonorrhoea. Missed treatment occurred in 4/155 (2.6%) of chlamydia and 5/158 (3.2%) of gonorrhoea consultations.CONCLUSIONThe new partner management protocol substantially reduced unnecessary antibiotic treatment for chlamydia and gonorrhoea. The majority of confirmed infections still received appropriate treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.